<DOC>
	<DOC>NCT00038922</DOC>
	<brief_summary>To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis. To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy tissue samples.</brief_summary>
	<brief_title>Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<criteria>Documented, signed informed consent to participate in this study Age greater than or equal to 18 years Documented diagnosis of ulcerative colitis by standard clinical criteria, including endoscopy (either flexible sigmoidoscopy or colonoscopy, sufficient to define the proximal limit of disease) with biopsy Crohn's disease Ulcerative proctitis Ulcerative colitis extending beyond the splenic flexure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Left-Sided</keyword>
	<keyword>Ulcerative</keyword>
	<keyword>Colitis</keyword>
</DOC>